Switch theme
Sign up to access all valuation multiples
Imugene Ltd specializes in a clinical-stage immuno-oncology company. Its products include HER-Vaxx, PD1-Vaxx, CF33 and CF33 CD19. HER-Vaxx is a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment is the Research and Development of oncolytic immunotherapies.
1986
3
LTM Revenue $1.6M
LTM EBITDA -$83.9M
$60.7M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Imugene has a last 12-month revenue (LTM) of $1.6M and a last 12-month EBITDA of -$83.9M.
In the most recent fiscal year, Imugene achieved revenue of n/a and an EBITDA of -$91.5M.
Imugene expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Imugene valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.6M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | $1.6M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$83.9M | XXX | -$91.5M | XXX | XXX | XXX |
| EBITDA Margin | -5224% | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$82.1M | XXX | -$93.6M | XXX | XXX | XXX |
| EBIT Margin | -5114% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$68.7M | XXX | -$96.2M | XXX | XXX | XXX |
| Net Margin | -4281% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Imugene's stock price is AUD 0 (or $0).
Imugene has current market cap of AUD 115M (or $73.9M), and EV of AUD 94.5M (or $60.7M).
See Imugene trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $60.7M | $73.9M | XXX | XXX | XXX | XXX | $-0.01 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Imugene has market cap of $73.9M and EV of $60.7M.
Imugene's trades at n/a EV/Revenue multiple, and -1.0x EV/EBITDA.
Equity research analysts estimate Imugene's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Imugene has a P/E ratio of -1.1x.
See valuation multiples for Imugene and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $73.9M | XXX | $73.9M | XXX | XXX | XXX |
| EV (current) | $60.7M | XXX | $60.7M | XXX | XXX | XXX |
| EV/Revenue | 37.8x | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -0.7x | XXX | -1.0x | XXX | XXX | XXX |
| EV/EBIT | -0.7x | XXX | -0.7x | XXX | XXX | XXX |
| EV/Gross Profit | 37.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.1x | XXX | -0.9x | XXX | XXX | XXX |
| EV/FCF | -1.0x | XXX | -1.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialImugene's revenue per employee in the last FY averaged n/a, while opex per employee averaged $31.2M for the same period.
Imugene's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Imugene's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Imugene and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -5224% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $31.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| CSL | XXX | XXX | XXX | XXX | XXX | XXX |
| Prescient Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| GSK India | XXX | XXX | XXX | XXX | XXX | XXX |
| AstraZeneca India | XXX | XXX | XXX | XXX | XXX | XXX |
| European Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Imugene acquired XXX companies to date.
Last acquisition by Imugene was XXXXXXXX, XXXXX XXXXX XXXXXX . Imugene acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Imugene founded? | Imugene was founded in 1986. |
| Where is Imugene headquartered? | Imugene is headquartered in Australia. |
| How many employees does Imugene have? | As of today, Imugene has 3 employees. |
| Who is the CEO of Imugene? | Imugene's CEO is Ms. Leslie Chong. |
| Is Imugene publicy listed? | Yes, Imugene is a public company listed on ASX. |
| What is the stock symbol of Imugene? | Imugene trades under IMU ticker. |
| When did Imugene go public? | Imugene went public in 1993. |
| Who are competitors of Imugene? | Similar companies to Imugene include e.g. CSL, Prescient Therapeutics, GSK India, AstraZeneca India. |
| What is the current market cap of Imugene? | Imugene's current market cap is $73.9M |
| What is the current revenue of Imugene? | Imugene's last 12 months revenue is $1.6M. |
| What is the current EV/Revenue multiple of Imugene? | Current revenue multiple of Imugene is 37.8x. |
| Is Imugene profitable? | Yes, Imugene is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Imugene? | Imugene's last 12 months EBITDA is -$83.9M. |
| What is Imugene's EBITDA margin? | Imugene's last 12 months EBITDA margin is -5224%. |
| What is the current EV/EBITDA multiple of Imugene? | Current EBITDA multiple of Imugene is -0.7x. |
| What is the current FCF of Imugene? | Imugene's last 12 months FCF is -$61.5M. |
| What is Imugene's FCF margin? | Imugene's last 12 months FCF margin is -3832%. |
| What is the current EV/FCF multiple of Imugene? | Current FCF multiple of Imugene is -1.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
